Nieuws en video's - DYNAVAX TECHNOLOGIES - Engels - Pagina 5

Dynavax to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire EMERYVILLE, Calif., Sept. 9, 2021 EMERYVILLE, Calif. , Sept. 9, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021 . The on...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., Sept. 2, 2021 EMERYVILLE, Calif. , Sept. 2, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 224,000 shares of Dynavax common stock as inducements to 8 newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on September 1,...

Thinking about buying stock in Skillz, Rigel Pharmaceuticals, Dynavax Technologies, Bellicum Pharmaceuticals, or Baudax Bio? PR Newswire NEW YORK, Sept. 1, 2021 NEW YORK , Sept. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SKLZ, RIGL, DVAX, BLCM, and BXRX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. SKLZ:...

Thinking about buying stock in PainReform, Gap, Multiplan, Aterian, or Dynavax Technologies? PR Newswire NEW YORK, Aug. 27, 2021 NEW YORK , Aug. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRFX, GPS, MPLN, ATER, and DVAX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. PRFX:...

Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 Adjuvant - Approximately 600,000 people are anticipated to receive the Medigen vaccine this week - MVC-COV1901 is a subunit vaccine comprised of recombinant SARS-CoV-2 S-2P antigen adjuvanted with CpG 1018® adjuvant - Medigen received Taiwan Emergency Use Authorization and approval for inclusion in Taiwan's COVID-19 vaccine immunization program in July PR Newswire TAIPEI, Taiwan and...

Dynavax Announces Second Quarter 2021 Financial Results - Second quarter 2021 total revenue of $52.8 million, which includes HEPLISAV-B's highest quarterly revenue to date at $13.7 million - Executed multiple commercial supply agreements for CpG 1018® adjuvant with our COVID-19 vaccine collaborators - Conference call to be held today at 4:30 p.m. ET/1:30 p.m. PT PR Newswire EMERYVILLE, Calif., Aug. 4, 2021 EMERYVILLE, Calif. , Aug. 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., Aug. 3, 2021 EMERYVILLE, Calif. , Aug. 3, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 438,000 shares of Dynavax common stock as inducements to 44 newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on August 2, 2021...

Dynavax to Report Second Quarter 2021 Financial Results and Host Conference Call on August 4, 2021 PR Newswire EMERYVILLE, Calif., July 21, 2021 EMERYVILLE, Calif. , July 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2021 financial results on Wednesday, August 4, 2021 , after the U.S. financial markets close. Dynavax will host a conference call and live...

Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate Biological E to purchase CpG 1018 adjuvant from Dynavax for use in the commercial production of Biological E's COVID-19 vaccine candidate, CORBEVAX™ PR Newswire EMERYVILLE, Calif. and HYDERABAD, India, July 6, 2021 EMERYVILLE, Calif. and HYDERABAD, India , July 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Dynavax, Nasdaq: DVAX), a...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., July 2, 2021 EMERYVILLE, Calif. , July 2, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 51,000 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on July 1, 2021 at an...

Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate - Clover to procure CpG 1018 adjuvant from Dynavax for use in the commercial production of Clover's COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum) - Pending conditional regulatory approvals, Clover expects to commence product launch of SCB-2019 (CpG 1018/Alum) by the end of 2021 PR Newswire CHENGDU, China, and EMERYVILLE, Calif., June 30, 2021 CHENGDU, China , and...

Dynavax Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., June 29, 2021 EMERYVILLE, Calif. , June 29, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that, in connection with the appointment of John Slebir as Senior Vice President, General Counsel on June 28, 2021 , the Company granted him a non-statutory stock option to purchase 300,000 shares of Dynavax common stock. The stock option has a 7-year term and vests...

Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference PR Newswire EMERYVILLE, Calif., June 9, 2021 EMERYVILLE, Calif. , June 9, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present virtually at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 3:50 p.m....

Dynavax to Present at the William Blair 41st Annual Growth Stock Conference PR Newswire EMERYVILLE, Calif., May 19, 2021 EMERYVILLE, Calif. , May 19, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer , Chief Executive Officer, will participate in a virtual fireside chat at the William Blair 41th Annual Growth Stock Conference on Tuesday, June 1, 2021 at 2:40...

Dynavax Announces Pricing of $200 Million Convertible Senior Notes Offering PR Newswire EMERYVILLE, Calif., May 11, 2021 EMERYVILLE, Calif., May 11, 2021 /PRNewswire/ -- Dynavax Technologies Corporation ("Dynavax") (Nasdaq: DVAX) today announced the pricing of $200.0 million aggregate principal amount of 2.50% convertible senior notes due 2026 (the "notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of...

Dynavax Announces Proposed Private Offering of $200 Million of Convertible Senior Notes PR Newswire EMERYVILLE, Calif., May 10, 2021 EMERYVILLE, Calif., May 10, 2021 /PRNewswire/ -- Dynavax Technologies Corporation ("Dynavax") (Nasdaq: DVAX) today announced that it intends to offer, subject to market conditions and other factors, $200 million aggregate principal amount of convertible senior notes due 2026 (the "notes") in a private placement to persons reasonably believed to be qualified...

Dynavax Announces First Quarter 2021 Financial Results - First quarter 2021 total revenue of $83.3 million, driven by strong execution in the CpG 1018 adjuvant business - Conference call to be held today at 4:30 p.m. ET/1:30 p.m. PT PR Newswire EMERYVILLE, Calif., May 6, 2021 EMERYVILLE, Calif. , May 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., May 4, 2021 EMERYVILLE, Calif. , May 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 148,500 shares of Dynavax common stock as inducements to seven newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on May 3, 2021 at...

HEPLISAV-B Post-Marketing Observational Study Results Presented at 2021 Annual Conference on Vaccinology Research (ACVR) - Data provide reassurance about the real-world safety of HEPLISAV-B in adults PR Newswire EMERYVILLE, Calif., April 27, 2021 EMERYVILLE, Calif. , April 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the results of the post-marketing study assessing...

Dynavax to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021 PR Newswire EMERYVILLE, Calif., April 22, 2021 EMERYVILLE, Calif. , April 22, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report first quarter 2021 financial results on Thursday, May 6, 2021 , after the U.S. financial markets close. Dynavax will host a conference call and live audio...